Ankylosing spondylitis is a form of chronic inflammation of the spine and the sacroiliac joints.

The sacroiliac joints are located at the base of the low back where the sacrum (the bone directly above the tailbone) meets the iliac bones (bones on either side of the upper buttocks) of the pelvis.

Chronic inflammation in these areas causes pain and stiffness in and around the spine, including the neck, middle back, lower back, and buttocks. Over time, chronic inflammation of the spine (spondylitis) can lead to a complete cementing together (fusion) of the vertebrae, a process referred to as ankylosis. Ankylosis causes loss of mobility of the spine.

Ankylosing spondylitis is also a systemic disease, meaning it can affect tissues throughout the body, not just the spine. Accordingly, it can cause inflammation in and injury to other joints away from the spine manifest as arthritis, as well as to other organs, such as the eyes, heart, lungs, and kidneys.

Ankylosing spondylitis shares many features with several other arthritis conditions, such as psoriatic arthritis, reactive arthritis (formerly called Reiter’s disease), and arthritis associated with Crohn’s disease and ulcerative colitis.

Each of these arthritic conditions can cause disease and inflammation in the spine, other joints, eyes, skin, mouth, and various organs. In view of their similarities and tendency to cause inflammation of the spine, these medical conditions are collectively referred to as “spondyloarthropathies.”

Ankylosing spondylitis is considered one of the many rheumatic diseases because it can cause symptoms involving muscles and joints.

Ankylosing spondylitis is two to three times more common in men than in women. In women, joints away from the spine are more frequently affected than in men. Ankylosing spondylitis affects all age groups, including children. When it affects children, it is referred to as juvenile ankylosing spondylitis. The most common age of onset of symptoms is in the second and third decades of life. Ankylosing spondylitis (AS) and has been referred to as Bechterew’s disease.

Life expectancy for ankylosing spondylitis is the same as the general population, except in those with very severe disease. Ankylosing spondylitis patients with the most serious form of disease, or who develop certain complications, can have a shortened life expectancy.

The tendency to develop ankylosing spondylitis is believed to be genetically inherited, and a majority (nearly 90%) of patients with ankylosing spondylitis are born with a gene known as the HLA-B27 gene.

Blood tests have been developed to detect the HLA-B27 gene marker and have furthered our understanding of the relationship between HLA-B27 and ankylosing spondylitis. The HLA-B27 gene appears only to increase the tendency of developing ankylosing spondylitis, while some additional factor(s), perhaps environmental factors, are necessary for the disease to appear or become expressed. For example, while 7% of the United States population has the HLA-B27 gene, only 1% of the population actually has the disease ankylosing spondylitis.

Other genes have been identified that are associated with ankylosing spondylitis, including ARTS1 and IL23R. These genes seem to play a role in influencing immune function. It is anticipated that by understanding the effects of each of these known gene risk factors.

Allopathic researchers are trying to discovering a cure for ankylosing spondylitis; while in Homeopathy, there are many confirmed medicines and treatments of ankylosing spondylitis.

How inflammation occurs and persists in different organs and joints in ankylosing spondylitis is a subject of active health research. Each individual tends to have their own unique pattern of presentation and activity of the illness.

The initial inflammation may be a result of an activation of the body’s immune system, perhaps by a preceding bacterial infection or a combination of infectious microbes. Once activated, the body’s immune system becomes unable to turn itself off, even though the initial bacterial infection may have long subsided.

Chronic tissue inflammation resulting from the continued activation of the body’s own immune system in the absence of active infection is the hallmark of an inflammatory autoimmune disease.

Symptoms

The symptoms of ankylosing spondylitis are related to inflammation of the spine, joints, and other parts of the body.

Fatigue is a common symptom associated with active inflammation. Inflammation of the spine causes pain and stiffness in the low back, upper buttock area, neck, and the remainder of the spine. The onset of pain and stiffness is usually gradual and progressively worsens with loss of range of motion noticeable over months. Occasionally, the onset is rapid and intense (flare-up). Lumbar pain (low back pain) and buttock pain are common manifestations of active inflammation in the lumbar spine and sacroiliac joints.

The symptoms of pain and stiffness are often worse in the morning or after prolonged periods of inactivity. Motion, heat, and a warm shower often reduces pain and stiffness in the morning. Because ankylosing spondylitis often affects adolescents, the onset of low back pain is sometimes incorrectly attributed to athletic injuries in younger patients.

Those who have chronic, severe inflammation of the spine can develop a complete bony fusion of the spine (ankylosis). Once fused, the pain in the spine disappears, but the affected individual has a complete loss of spine mobility. This might lead to a slight hunched forward posture. These fused spines are particularly brittle and vulnerable to breakage (fracture). A sudden onset of pain and mobility in the spinal area of these patients can indicate bone breakage. The lower neck (cervical spine) is the most common area for such fractures.

Chronic spondylitis and ankylosing cause forward curvature of the upper torso (thoracic spine), which limits breathing capacity. Spondylitis can also affect the areas where ribs attach to the upper spine, further limiting lung capacity. Ankylosing spondylitis can cause inflammation and scarring of the lungs, causing coughing and shortness of breath, especially with exercise and infections. (breathing difficulty can be a serious complication of ankylosing spondylitis).

People with ankylosing spondylitis can also have arthritis in joints other than the spine. This feature occurs more commonly in women. Patients may notice pain, stiffness, heat, swelling, warmth, and/or redness in joints such as the hips, knees, and ankles. Occasionally, the small joints of the toes can become inflamed or “sausage” shaped. Inflammation can occur in the cartilage around the breastbone (costochondritis) as well as in the tendons where the muscles attach to the bone (tendinitis) and in ligament attachments to bone (enthesitis).

Some people with this disease develop Achilles tendinitis, causing pain and stiffness in the back of the heel, especially when pushing off with the foot while walking upstairs. Inflammation of the tissues of the bottom of the foot, plantar fasciitis, occurs more frequently in people with ankylosing spondylitis.

Other areas of the body affected by ankylosing spondylitis include the eyes, heart, and kidneys. Patients with ankylosing spondylitis can develop inflammation of the iris (iritis), the colored portion of the eye. Iritis is characterized by redness and pain in the eye, especially when looking at bright lights. Recurrent attacks of iritis can affect either eye. In addition to the iris, the ciliary body and choroid of the eye can become inflamed; this is referred to as uveitis.

Iritis and uveitis can be serious complications of ankylosing spondylitis that can damage the eye and impair vision and may require an eye specialist’s (ophthalmologist) urgent care.

It should be noted that iritis and inflammation of the spine can occur in other forms of arthritis such as reactive arthritis [formerly known as Reiter’s syndrome], psoriatic arthritis, and the arthritis of inflammatory bowel disease).

A rare complication of ankylosing spondylitis involves scarring of the heart’s electrical system, causing an abnormally slow heart rate (referred to as heart block). A heart pacemaker may be necessary in these patients to maintain adequate heart rate and output. In others, the part of the aorta closest to the heart can become inflamed, resulting in leakage of the aortic valve. In this case, patients can develop shortness of breath, dizziness, and heart failure.

Advanced spondylitis can lead to deposits of protein material called amyloid into the kidneys and result in kidney failure. Progressive kidney disease can lead to chronic fatigue and nausea and can require removal of accumulated waste products in the blood by a filtering machine (dialysis).

Diagnosis

The diagnosis of ankylosing spondylitis is based on evaluating the patient’s symptoms, a physical examination, X-ray findings (plain X-rays as well as MRI studies), and blood tests.

The examination can demonstrate signs of inflammation and decreased range of motion of joints. This can be particularly apparent in the spine. Flexibility of the low back and/or neck can be decreased.

Further clues to the diagnosis are suggested by X-ray abnormalities of the spine and the presence of the genetic marker HLA-B27 identified by a blood test.

Other blood tests may provide evidence of inflammation in the body. For example, sedimentation rate is a nonspecific marker for inflammation throughout the body and is often elevated in inflammatory conditions such as ankylosing spondylitis.

X-ray tests of the sacroiliac joints can demonstrate signs of inflammation and erosion of bone. X-rays of the spine can progressively demonstrate straightening, “squaring” of the vertebrae, and end-stage fusion of one vertebra to the next (ankylosis). Fusion up and down the spine can lead to a “bamboo spine” appearance on X-ray tests with complete loss of mobility.

Urinalysis is often done to look for accompanying abnormalities of the kidney as well as to exclude kidney conditions that may produce back pain that mimics ankylosing spondylitis. Patients are also simultaneously evaluated for symptoms and signs of other related spondyloarthropathies, such as psoriasis, venereal disease, dysentery (reactive arthritis or Reiter’s disease), and inflammatory bowel disease (ulcerative colitis or Crohn’s disease).

The treatment of ankylosing spondylitis typically involves the use of medications to reduce inflammation and/or suppress immunity to stop progression of the disease, physical therapy, and exercise. Medications decrease inflammation in the spine and other joints and organs. Physical therapy and exercise help improve posture, spine mobility, and lung capacity.

Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to decrease pain and stiffness of the spine and other joints. Commonly used NSAIDs include indomethacin, tolmetin, sulindac, naproxen, and diclofenac.

Their common side effects include stomach upset, nausea, abdominal pain, diarrhea, and even bleeding ulcers. Myocardial infarction, and stroke. cardiovascular disease (increase 100% in 100% patients). Kidney/renal injury and failure, thrombogenic effect on platelet function. NSAIDs increase systolic blood pressure. Respiratory systems. Acute deterioration in asthma symptoms.  Comorbidity and polypharmacy increase with age, as does the incidence of chronic musculoskeletal conditions such as osteoarthritis, for which NSAIDs are often prescribed.  Liver impairment etc.

These medicines are frequently taken with food in order to minimize side effects.

In some people with ankylosing spondylitis, inflammation of joints excluding the spine (such as the hips, knees, or ankles) becomes the major problem. Inflammation in these joints may not respond to NSAIDs alone. For these individuals, the addition of disease-modifying antirheumatic drugs (DMARDs) that suppress the body’s immune system is considered. These medications, such as sulfasalazine, may bring about long-term reduction of inflammation. An alternative to sulfasalazine that is somewhat more effective is methotrexate, which can be administered orally or by injection.

Frequent blood tests are performed during methotrexate treatment because of its potential for toxicity to the liver, which can even lead to cirrhosis, and toxicity to bone marrow, which can lead to severe anemia.

Allopathic research has shown that for persistent ankylosing spondylitis with spinal involvement that is unresponsive to anti-inflammatory medications, both sulfasalazine and methotrexate are ineffective. Newer, effective medications for spine disease attack a messenger protein of inflammation called tumor necrosis factor (TNF). These TNF-blocking medications have been shown to be extremely effective for treating ankylosing spondylitis by stopping disease activity, decreasing inflammation, and improving spinal mobility. Examples of these TNF-blockers include etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab. In 2016, adalimumab (Humira) was approved for the treatment of uveitis (inflammation in the eyes).

If nonsteroidal anti-inflammatory drugs (NSAIDs) are not effective in a patient whose condition is dominated by spinal inflammation (and 50% do respond), then biologic medications that inhibit tumor necrosis factor (TNF inhibitors) or that inhibit interleukin 17 are used.

All TNF inhibitors, including Remicade, Enbrel, Humira, Cimzia, and Simponi can be effective in treating ankylosing spondylitis. The improvement that results for TNF inhibition is sustained during years of treatment. If the TNF inhibitors are discontinued, for whatever reason, relapse of disease occurs in virtually all patients within a year. If TNF inhibitor is then resumed, it is typically effective. Secukinumab (Cosentyx) and ixekizumab (Taltz) are biologic medications that inhibit interleukin 17. Both secukinumab and ixekizumab are indicated to treat ankylosing spondylitis. Doctors administer both of the interleukin 17-inhibiting medications as subcutaneous injections.

Oral or injectable corticosteroids (cortisone) are potent anti-inflammatory agents and can effectively control spondylitis and other inflammations in the body.

Unfortunately, corticosteroids can have serious side effects when used on a long-term basis. So they are typically used for short periods when possible. These side effects include cataracts, thinning of the skin and bones (osteoporosis), easy bruising, infections, diabetes, and destruction of large joints, such as the hips.

Inflammation and diseases in other organs are treated separately. For example, inflammation of the iris of the eyes (iritis or uveitis) may require cortisone eye drops (Pred Forte) and high doses of cortisone by mouth. Additionally, atropine eye drops are often given to relax the muscles of the iris. Sometimes injections of cortisone into the affected eye are necessary when the inflammation is severe. Heart disease in patients with ankylosing spondylitis, such as heart block, may require a pacemaker placement or medications for congestive heart failure.

Finally, orthopedic surgery may be required when there is severe disease of the hip joints and spine.

Serious and common adverse effects of all anti-TNF agents include headaches. Serious infections are a significant and concerning adverse effect of anti-TNF agents and may include bacterial, fungal, viral, or atypical infections. These infections may be fatal. Infections are more common in patients receiving multiple immunosuppressive agents such as methotrexate or corticosteroids combined with anti-TNF agents. Reports exist of the reactivation of tuberculosis and viral hepatitis B and C, rashes, anemia, transaminitis, certain fungal infections such as blastomycosis, coccidioidomycosis, upper respiratory tract infections, sinusitis, cough, pharyngitis, diarrhea, nausea,  risk of malignancies, especially lymphomas. higher risk of non-melanoma skin cancers and abdominal pain.

Initial studies of anti-TNF agents in patients with RA and congestive heart failure NYHA Class III or IV showed poor cardiac outcomes, including increased mortality, an increase in hospitalizations, and a worsening of CHF (avoid anti-TNF agents in patients with severe congestive heart failure (NYHA Class III or IV) and use them cautiously in patients with mild congestive heart failure).

The common manifestations of drug-induced lupus from anti-TNF agents are kin rash, thrombocytopenia, leukopenia, hypocomplementemia, and rarely hemolytic anemia. Demyelinating disorders, including optic neuritis, multiple sclerosis (including exacerbation of underlying multiple sclerosis), myelitis, encephalitis, Guillain-Barre syndrome, transverse myelitis, and chronic inflammatory demyelinating polyneuropathy, in patients taking anti-TNF agents. Anti-TNF agents should be avoided or used with extreme caution in patients with an underlying demyelinating disorder.

Anti-TNF agents have been labeled as Class B pregnancy risk by the FDA; all other anti-TNF agents cross the placenta, exposing the infant to the anti-TNF agent. Anti-TNF agent use in pregnancy should be a consideration only if there is a clear and strong indication.

Several major points about the treatment of ankylosing spondylitis deserve emphasis. There is an early, underdiagnosed stage of spondylitis that occurs before plain X-ray testing can detect classic changes. Patients who are treated earlier respond better to treatments. Current disease-modifying drugs such as methotrexate, sulfasalazine, and leflunomide, which can be effective for joint inflammation of joints away from the spine, are not effective for spinal inflammation.

Homeopathic Treatment Of Ankylosing Spondylitis 

The aim of homeopathy is not only to treat ankylosing spondylitis but to address its underlying cause and its bad effects on the organs too. The symptoms listed against each medicine may not be directly related to the disease because in homeopathy general symptoms and constitutional indications are taken into account for selecting a remedy.

Complications

In severe ankylosing spondylitis, new bone forms as part of the body’s attempt to heal.

This new bone gradually bridges the gap between vertebrae and eventually fuses sections of vertebrae. Those parts of the spine become stiff and inflexible.

Fusion can also stiffen the rib cage, restricting lung capacity and function.

Eye inflammation (uveitis). One of the most common complications of ankylosing spondylitis, uveitis can cause rapid-onset eye pain, photophobia (sensitivity to light) and blurred vision.

Compression fractures. Some people’s bones weaken during the early stages of ankylosing spondylitis.

These weakened vertebrae can crumple, increasing the severity of a stooped posture. Vertebral fractures can put pressure on and possibly injure the spinal cord and the nerves that pass through the spine.

Heart problems. Ankylosing spondylitis can cause inflammation in aorta. The inflamed aorta can enlarge to the point that it distorts the shape of the aortic valve in the heart, which impairs its function.

The inflammation associated with ankylosing spondylitis increases the risk of mortality in general.

The outlook for patients with ankylosing spondylitis is very much dependent upon the location and severity of its manifestations.

The prognosis is best for those who treats Homeopathically, maintain close monitoring with the treating doctors and who incorporate physical activities designed to maintain mobility.

Quit smoking, eating/sniffing tobacco is essential for the best long-term outcome.

It has been found that people with ankylosing spondylitis have somewhat of an increased health risk for coronary artery disease. This increased risk appears to be caused by chronic inflammation. Therefore, it is important to optimize all modifiable cardiac risks, including elevated blood pressure and cholesterol.